Mitapivat PDUFA Date for Sickle Cell Disease Extended to February 2027
Agios Pharmaceuticals announced the FDA extended the PDUFA goal date for mitapivat in sickle cell disease to February 2027, a 3-month delay. The extension follows a major amendment to the sNDA, which was submitted under accelerated approval. Agios maintains confidence in mitapivat's potential, citing positive RISE UP trial results. The company expects mitapivat to be a significant growth driver.
How this was made
The 30-second read
Why it matters
Regulatory delay may delay revenue contribution from the new indication, affecting short‑term earnings forecasts.
Market read
The news is a primary regulatory update for a biotech firm, likely influencing its stock price in the near term.
What to watch
Potential for Agios to leverage existing commercial infrastructure for a faster rollout once approved.
Background
Agios Pharmaceuticals (NASDAQ: AGIO) is developing mitapivat for sickle cell disease, building on its existing PK deficiency product Pyrukynd.
Ticker impact
FDA extended the PDUFA goal date for Agios' mitapivat in sickle cell disease to February 1, 2027, delaying potential market launch.
likely downward pressure as investors reassess near‑term growth expectations
Regulatory delay reduces near‑term upside; the market had anticipated a Q4 2026 decision. No new positive data offset the setback.
Market effects
May temper enthusiasm for biotech stocks awaiting FDA decisions on hematology therapies.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond investors tracking FDA pipelines.
Counterpoint
If the extension reflects thorough review, the eventual approval could be more robust, offering upside on a later timeline.
Key entities
- CompanyAgios Pharmaceuticals
Developer of mitapivat, seeking FDA approval for sickle cell disease indication.
- RegulatorFDA
Extended the PDUFA target date, indicating additional review requirements.